Apabetalone

阿帕他酮

Report date: 2025/01/15 11:09:44
NME

Base Information

Drug NameApabetalone
Drug Alias Name阿贝他酮apabetalonaapabetalonum8R4A7GDZ1D (UNII code)RVX-000222 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain-containing protein 4 inhibitorsBromodomain and extra terminal domain protein inhibitors
TargetsBromodomain-containing protein 4Bromodomain and extra terminal domain protein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeDyslipidemias +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[23] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesResverlogix Corp
China Registration ClassN/A

Develop Information

Active CompaniesDohmen Life Science ServicesRevue Juridique Des Etudiants Et Etudiantes De L'Universite Laval IncResverlogix Corp
Inactive CompaniesN/A
Active IndicationsPost-Acute COVID-19 SyndromeDiabetes Mellitus, Type 2Coronary Artery Disease +[5] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)DyslipidemiasDiabetes Mellitus +[7] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG